GA-FINEOS
14.7.2020 15:17:03 CEST | Business Wire | Press release
FINEOS Corporation (ASX:FCL ), the leading core platform for life, accident and health insurance globally, today announces the appointment of Allison Morgan as Senior Sales Executive to the FINEOS North American team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005639/en/
Allison brings nearly 25 years of proven experience as an accomplished absence and disability sales leader and consultant with powerful relationship building, negotiation, communication and presentation skills. She has a proven track record and demonstrated ability to obtain, grow and retain a customer base to support organizational objectives.
In her new role at FINEOS, Allison will be responsible for developing new business clients for FINEOS Claims , FINEOS Absence and FINEOS AdminSuite . Alison’s expertise in absence management is especially important as Integrated Disability and Absence management (IDAM ) becomes a major product offering for insurance carriers serving the Employee Benefits space. She will work closely with brokers, consultants, and complementary product vendors within the Employee Benefits market.
FINEOS AdminSuite is a modern integrated core processing system that consists of absence, claims, payments, billing, policy, and provider administration – all of which are configurable to operate independently or optimally as a full core suite as part of the SaaS delivered FINEOS Platform , powered by AWS.
Prior to joining FINEOS, Allison worked for eight years at Reed Group, a Guardian company, where she was responsible for new business development of absence management software and outsourcing opportunities, focusing on the design of short and long term disability and absence programs for companies with 5,000 employees and above. Previously, she held senior positions in large insurance companies and brokers including MetLife and Aon Hewitt.
“We are delighted to welcome Allison to the FINEOS team and look forward to working closely with her to continue to help insurance carriers in North America realize the benefits of partnering with FINEOS,” said Michael Kelly , CEO, FINEOS. “In addition to having to transform their business to a fully digital model that delivers excellent customer experience, insurers need to provide risk-based products integrated with comprehensive service offerings that include non-traditional products and services, like IDAM. Our 100% commitment to the Employee Benefits market requires experienced people with a strong understanding of the market today and where it is going in the future. Allison brings that next level of focus on IDAM within the Employee Benefits market for FINEOS. We couldn’t be more pleased to have her on board.”
“I am thrilled to join FINEOS, who is known throughout the insurance industry as the leading provider of core technology solutions. As insurers evaluate their current technology, they are recognizing a critical need to effectively and efficiently meet the growing needs of their customers, both employees and employers, who continue to demand a best-in-class product, service and claims experience enabled by modern technology,” said Allison Morgan, senior sales executive for North America. “Additionally, as entitlement laws continue to pass, insurers need state-of-the-art technology solutions to maintain compliance with various federal, state and local laws. FINEOS brings together all of those considerations to create efficient and robust technology solutions enabling the insurer or Third-Party Administrator to focus on better serving their customers and partnering with FINEOS to achieve their growth objectives.”
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides clients full end to end core insurance administration and includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005639/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stitch Raises $25M Series A Led by Andreessen Horowitz14.5.2026 09:00:00 CEST | Press release
In a16z’s first investment in the GCC, the Riyadh-based fintech positions itself as the unified infrastructure layer for financial institutions worldwide Stitch, the operating system built for modern financial institutions, today announced it has raised $25 million in Series A funding led by Andreessen Horowitz (a16z). The investment marks a16z’s first in the GCC and brings Stitch’s total funding to $35 million. In addition to a16z, existing investors Arbor Ventures, COTU Ventures, Raed Ventures, and SVC also participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514070694/en/ Mohamed Oueida - Founder & CEO, Stitch (Photo: AETOSWire) Despite spending over $1 trillion on digital transformation in the last three years, most financial institutions are still running on the same fragmented, legacy infrastructure that has defined the sector for decades. Globally, banks spend $700 billion a year on technology
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Third Consecutive Year14.5.2026 06:01:00 CEST | Press release
AB InBev Holds 8 of the Top 10 Most Valuable Beer Brands Globally Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar's BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513211378/en/ In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
